Nusinersen

Analysis of data from the SMArtCARE registry demonstrated that nusinersen treatment positively affected motor function over a 38-month period in

Spinraza (nusinersen) has been approved by China’s National Medical Product Administration (NMPA) for the treatment of the spinal muscular atrophy